Generic Vyvanse (Lisdexamfetamine): Shortage Status, API Quotas, and NADAC Price Erosion

As of June 10, 2026, generic lisdexamfetamine capsule prices have eroded by approximately 75% relative to brand Vyvanse, with generic NADAC prices averaging $2.73 to $3.12 per capsule compared to brand Vyvanse's uniform price of ~$12.35. Yet supply remains constrained: the openFDA shortages database lists 108 lisdexamfetamine presentations (90 capsules and 18 chewable tablets) under a Current shortage that has persisted since 2023. While 77 of those presentations read Available at the snapshot date, 29 carry Limited Availability — concentrated at labelers such as Solco, Hikma, Elite Laboratories, and Novadoz — and 2 are Unavailable, reflecting DEA-administered Aggregate Production Quota (APQ) bottlenecks at the active pharmaceutical ingredient (API) level.

Although generic Vyvanse has achieved significant price erosion (averaging ~75% discounts), the DEA quota framework and API supply constraints prevent the market from fully clearing, creating a persistent "pricing discount alongside spotty inventory" paradox for retail pharmacies. In a typical competitive market, a supply shortage leads to price inflation. However, because generic lisdexamfetamine pricing is governed by multi-tier commercial pharmacy benefit manager (PBM) contracts and statutory Medicaid rebate rules, surveyed pharmacy acquisition costs have collapsed even as many patients struggle to fill a specific manufacturer's product.

This article analyzes the retail pricing erosion margins across all capsule strengths, the structural factors in the openFDA drug shortages database, the DEA's regulatory production caps, and the operational implications for pharmacy directors, payers, and clinical prescribers.

---

How have generic lisdexamfetamine NADAC prices eroded relative to brand Vyvanse?

In August 2023, the U.S. Food and Drug Administration (FDA) approved multiple generic versions of Takeda’s blockbuster ADHD and Binge Eating Disorder (BED) treatment, Vyvanse (lisdexamfetamine dimesylate). Approximately 14 generic manufacturers launched capsule and chewable formulations simultaneously onto the market. This massive wave of generic entrants initiated a rapid pricing cliff, typical of high-volume small-molecule blockbusters.

The NADAC Pricing Cliff

The Centers for Medicare & Medicaid Services (CMS) monitors actual invoice prices paid by retail community pharmacies through the National Average Drug Acquisition Cost (NADAC) database. An analysis of the June 10, 2026 NADAC file reveals the current retail pricing structure for brand Vyvanse capsules and generic lisdexamfetamine capsules across all seven FDA-approved capsule strengths.

The data reveals that brand Vyvanse maintains a uniform price of approximately $12.35 per capsule across all strengths, reflecting Takeda's branded pricing strategy. In contrast, the surveyed generic acquisition costs range from $2.73 per capsule (for the 20 mg strength) to $3.12 per capsule (for the 30 mg strength). This represents a steep price erosion, delivering a generic discount of 74.7% to 77.9% off the branded baseline.

The following table details the strength-by-strength pricing comparison and calculated discount margins from the June 10, 2026 NADAC snapshot:

Payer pharmacy directors and benefits managers utilize these figures for using CMS NADAC files to track brand-to-generic pricing cliffs. The data confirms that from a cost-per-tablet perspective, the generic market has behaved efficiently, stripping away more than three-quarters of the branded cost within three years of patent expiry.

The Pricing-Shortage Paradox

The central economic paradox of the generic lisdexamfetamine market is that this price collapse has occurred in the midst of a severe, multi-year supply shortage. In standard economic theory, when supply is scarce and demand remains high, prices rise. In the U.S. pharmaceutical market, however, several institutional mechanisms prevent shortage-driven price spikes for generic small molecules:

1. PBM Maximum Allowable Cost (MAC) Lists: PBMs set MAC limits on what they will reimburse retail pharmacies for generic drugs. If a pharmacy tries to buy generic lisdexamfetamine at a premium from a secondary wholesaler to secure inventory, the PBM's MAC list will not reimburse the higher cost. The pharmacy is forced to purchase at or near the contracted rate, or face a financial loss on the dispense.
2. Wholesaler Prime Vendor Agreements: Independent and chain pharmacies purchase drugs through primary wholesalers (e.g., McKesson, AmerisourceBergen, Cardinal) under long-term contracts that tie pricing to specific volume commitments. Wholesalers cannot arbitrarily inflate generic pricing during a shortage without violating these prime vendor agreements.
3. Medicaid Best Price Rules: Under federal law, manufacturers must report their "Best Price" to Medicaid. If a manufacturer raises prices for private buyers, they may trigger increased rebate liabilities across their entire Medicaid book of business, neutralizing the short-term gains of a shortage-driven price hike.

---

Why does generic Vyvanse remain on the FDA drug shortages list?

The openFDA drug shortages database represents the official federal registry of active drug supply disruptions. A query of the June 10, 2026 database snapshot shows lisdexamfetamine as one of the largest single-molecule entries on the list, and it is the molecule our broader Schedule II stimulant shortage and DEA quota analysis identifies as having the deepest shortage by raw record count. This article drills into the lisdexamfetamine-specific breakdown that underpins that class-level finding.

• Active Shortage Records: There are 108 distinct NDC presentations for lisdexamfetamine on the Current shortage list — 90 capsule and 18 chewable tablet presentations across seven dosage strengths.
• Companies on the List: The 108 presentations span 14 companies — 13 generic labelers (Teva, Sun Pharmaceutical, Lannett, Solco, Hikma, SpecGx, Alvogen, Elite Laboratories, Apotex, Rhodes, Mylan/Viatris, Novadoz, and Amneal) plus the branded manufacturer Takeda.
• Availability Statuses: As of June 10, 2026, 77 of the 108 presentations are marked Available, while 29 carry Limited Availability and 2 are Unavailable — meaning roughly 29% of presentations are not fully available at a given moment. Branded Takeda Vyvanse and Sun Pharmaceutical's generics report all of their presentations as Available, while the constraint is concentrated in specific labelers whose entire lisdexamfetamine lineups sit on Limited Availability.

The following table lists every company with lisdexamfetamine presentations on the openFDA shortage list and their availability breakdown:

Two points follow from this distribution. First, the shortage is not a uniform "every generic is out of stock" condition — at the snapshot date most presentations read Available, which is exactly why surveyed acquisition costs (NADAC) have collapsed even as many patients still cannot reliably fill a specific manufacturer's product. Second, the patient-experienced scarcity is driven by a handful of fully-constrained labelers (Solco, Hikma, Elite, and Novadoz) combined with PBM formularies that often force a pharmacy to dispense a single preferred manufacturer. When that one preferred NDC is on Limited Availability, the patient faces an empty shelf regardless of how many other labelers are technically Available.

Shortage Reason: API Constraints, Not Sterility Failures

The FDA's shortage reporting for lisdexamfetamine ties the disruption to active pharmaceutical ingredient (API) supply rather than finished-dose manufacturing problems. This distinguishes the oral stimulant shortage from the sterile-injectable oncology and anesthesia shortages, which are typically driven by manufacturing sterility failures (particulate contamination, vial cracks). For lisdexamfetamine, the finished-dose plants have the tableting, capsuling, and packaging capacity to run — the bottleneck is upstream, in obtaining bulk lisdexamfetamine and its amphetamine precursor under DEA production caps. The openFDA /drug/shortages extract itself carries no per-record reason field, but FDA's separate 21 U.S.C. 356c notification framework formally identified "shortage of an active ingredient" as the basis for the lisdexamfetamine shortage, and a 2026 JAMA Health Forum analysis (Currie and Malinovskaya) traced the disruption to a sharp contraction in U.S. imports of amphetamine API rather than quota limits alone.

---

How do DEA active pharmaceutical ingredient quotas bottleneck generic supply?

To understand why generic manufacturers cannot secure the API needed to resolve the shortage, one must examine the regulatory framework established under the Controlled Substances Act (CSA) of 1970. Because lisdexamfetamine is an amphetamine derivative with a high potential for abuse and dependence, it is classified as a Schedule II controlled substance.

The Aggregate Production Quota (APQ) System

The Drug Enforcement Administration (DEA) is responsible for preventing the diversion of controlled substances while ensuring that the United States has an adequate supply for legitimate medical, scientific, and research needs. To achieve this, the DEA administers the Aggregate Production Quota (APQ) system:

1. APQ Determination: Each year, the DEA establishes an APQ for the total quantity of each Schedule II drug that can be manufactured in the United States. The APQ is calculated using a formula that considers historical sales, projected medical demand, export requirements, and a statutory inventory allowance (typically capped at 50% under 21 CFR 1303.24).
2. Individual Manufacturing Quotas (IMQs): Once the APQ is set, the DEA allocates Individual Manufacturing Quotas to specific bulk API manufacturers and Procurement Quotas to finished-dose manufacturers. A finished-dose labeler (such as Teva or Solco) cannot purchase more bulk API than their allocated Procurement Quota allows.
3. The Quota Cap: Even if a finished-dose manufacturer has idle machinery and orders from thousands of pharmacies, they are legally prohibited from purchasing additional raw material once they exhaust their annual DEA Procurement Quota.

Quota Adjustments and the Lag Time

In response to the persistent stimulant shortages, the DEA has implemented several upward adjustments to the APQ for lisdexamfetamine and d-amphetamine (the chemical precursor used to synthesize lisdexamfetamine):

• 2024 Adjustment: On September 5, 2024, the DEA raised the lisdexamfetamine APQ by approximately 24% following a formal letter from the FDA identifying an active-ingredient shortage.
• 2025 Adjustment: The DEA implemented a 22% increase for lisdexamfetamine in late 2025.
• 2026 Final Quota: On January 5, 2026, the DEA published its final order establishing the 2026 APQs, setting the lisdexamfetamine quota at 51,290,743 grams (51.29 million grams)—a significant increase from the initial proposals.

Despite these adjustments, shortages persist due to the backward-looking nature of the APQ calculation formula. The DEA's formula is calibrated to historical consumption data, creating a 12- to 18-month lag behind actual clinical demand.

Furthermore, the allocation of quota is rigid. If one manufacturer (such as Ascent Pharmaceuticals, which faced DEA regulatory halts over recordkeeping) is unable to utilize its quota, that quota cannot be easily or rapidly reallocated to other manufacturers who have excess manufacturing capacity. The result is a rigid system where the total quota allocated is underutilized, while active manufacturers remain bottlenecked by their individual caps.

The Procurement Quota Petition Process (Form 250)

When finished-dose generic manufacturers realize their allocated Procurement Quotas are insufficient to meet market demand, they must petition the DEA for a quota adjustment. This process is governed by 21 CFR 1303.12:

• Filing DEA Form 250: Manufacturers must submit DEA Form 250, requesting an amendment to their procurement quota. The application requires extensive documentation, including historical manufacturing records, current inventory levels, outstanding customer orders, and verified sales forecasts.
• Evaluation Windows: The DEA reviews these requests to ensure that approving the additional quota will not cause the total U.S. manufacturing volume to exceed the established APQ.
• Administrative Lag: The evaluation and approval process can take 60 to 90 days. During this window, generic manufacturers are unable to purchase bulk API. Wholesalers and pharmacies experience this administrative lag as a sudden "out of stock" notification, even when the manufacturer's facility is fully operational.

---

Historical Context of the Vyvanse Patent Cliff

The Vyvanse patent cliff represents one of the most anticipated events in modern neuropsychopharmacology. Branded Vyvanse was originally developed by New River Pharmaceuticals and acquired by Shire plc in 2007 for $2.6 billion. Takeda subsequently acquired Shire in January 2019, taking over the Vyvanse franchise.

The primary compound patent covering lisdexamfetamine dimesylate (U.S. Patent No. 7,153,887) expired in February 2023, and a pediatric exclusivity period extended the last barrier to generic entry through August 24, 2023. Under Hatch-Waxman rules, multiple generic manufacturers had filed Abbreviated New Drug Applications (ANDAs) containing Paragraph IV certifications. Rather than risking at-risk launches, generic developers entered into confidential settlement agreements with Shire/Takeda that timed entry to the end of that exclusivity.

This settlement structure created a "cliff-edge" entry: on August 25, 2023, the FDA approved and 14 manufacturers launched generic lisdexamfetamine capsules and chewable tablets simultaneously. This immediate multi-source entry is what initiated the rapid price erosion shown in the NADAC figures. However, because the DEA's APQ for lisdexamfetamine had been sized for a single supplier (Takeda) with predictable manufacturing yields and inventory buffers, distributing that same quota among 14 different entities with varying manufacturing efficiencies and supply chains caused immediate disruption, triggering the shortages that have persisted into 2026.

The PBM Rebate Wall and Brand Preference

Another factor that complicated the launch of generic lisdexamfetamine is the PBM "rebate wall." Following generic entry, Takeda offered aggressive rebates to major PBMs (such as CVS Caremark, Express Scripts, and OptumRx) to maintain preferred status for brand Vyvanse on commercial formularies:

• Branded Preference: In the first year of generic availability, several commercial formularies excluded generic NDCs or placed them on higher co-pay tiers, forcing patients to stay on the branded drug.
• Net-Cost Economics: PBMs preferred the brand because the net cost (WAC minus the manufacturer rebate) was lower than the initial acquisition cost of the generics.
• Generic Deficit: This brand-preferential formulary design initially depressed generic demand, which in turn influenced subsequent DEA quota allocations. When the shortages hit, patients trying to switch to generics faced a double block: PBMs that penalized generic utilization and pharmacies that had zero generic inventory.

---

Operational and Clinical Playbook for Access Teams

The intersection of price erosion and supply shortages creates a complex operational environment for healthcare systems, pharmacy managers, and clinicians. Managing Schedule II stimulant supply shortages and DEA quota controls requires proactive clinical and administrative strategies.

Clinical Management and Therapeutic Alternatives

For pediatric and adult ADHD patients, consistent therapy is critical for academic, professional, and social functioning. When a generic lisdexamfetamine stockout occurs, clinic access teams must coordinate with prescribers to implement therapeutic bridges:

• Therapeutic Substitution Protocols: Within the class of long-acting stimulants, patients may need to switch to alternative formulations (such as mixed amphetamine salts extended-release or methylphenidate formulations). Clinic access teams should pre-clear these therapeutic alternatives with payers to ensure that a switch does not trigger a new, lengthy prior authorization cycle.
• Formulation Switches (Capsules to Chewables): Generic chewable formulations sometimes carry different availability profiles than capsules. Clinicians can write prescriptions that permit substitution of chewable tablets for capsules if the capsule strengths are unavailable, although this may require pharmacy benefit adjustments due to different WAC pricing baselines.
• Dose-Strength Splitting: If a patient is prescribed 60 mg capsules but the pharmacy only has 30 mg capsules in stock, the clinician must write a new prescription for two 30 mg capsules daily. Because this represents a change in the quantity of units dispensed, PBM systems will flag it as a "high-dose" or "quantity limit" exception, requiring the clinic to submit a prior authorization override.
• DEA Electronic Prescription Transfers (One-Time Rule): Under a DEA final rule effective August 28, 2023 (21 CFR 1306.08), pharmacies may perform a one-time electronic transfer of an electronic prescription for a Schedule II–V controlled substance (such as lisdexamfetamine) to another retail pharmacy for initial filling, upon the patient's request. This is a major administrative relief during shortages: patients no longer need a new prescription from their prescriber if their primary pharmacy is out of stock, provided the transfer is communicated directly between two licensed pharmacists and stays in electronic form. Access teams should confirm the state allows it — some state pharmacy acts (Pennsylvania's, for example) still prohibit transferring Schedule II prescriptions regardless of the federal rule.

Payer Formulary Design and Generic Blocks

Pharmacy benefit managers (PBMs) frequently construct "exclusionary" formularies that mandate the use of a single preferred generic to secure maximum manufacturer rebates. However, during a systemic drug shortage, this rigid structure leads to immediate access failures:

• PBM Preferred Lists: If a PBM forces a pharmacy to dispense only Teva’s generic lisdexamfetamine, but Teva is on allocation, the patient cannot fill their prescription even if the pharmacy has Solco's generic in stock.
• Formulary Flexibility: Payers should implement temporary "shortage overrides" that permit the dispensing of any available generic NDC on the market without penalty to the patient or pharmacy.
• Brand-Name Overrides: In severe cases, payers may temporarily cover brand Vyvanse at the generic co-pay tier when the clinic documents that no generic NDCs are available within a reasonable geographic radius.

---

Detailed FAQ Section

Which generic Vyvanse manufacturers are currently experiencing limited availability?

According to the June 10, 2026 openFDA drug shortages snapshot, four generic manufacturers report their entire lisdexamfetamine lineups as Limited Availability: Solco Healthcare, Hikma Pharmaceuticals, Elite Laboratories, and Novadoz Pharmaceuticals. Two others are partially constrained — Rhodes Pharmaceuticals (two of seven presentations Unavailable) and Lannett and Teva (each with one of seven presentations on Limited Availability). The remaining labelers (Sun, SpecGx, Alvogen, Apotex, Mylan/Viatris, and Amneal) and brand Takeda report all of their presentations as Available. The practical catch is that a patient's pharmacy is often locked to a single PBM-preferred manufacturer, so even one constrained labeler can produce an unfilled prescription.

Why is there a wide price spread between chewable and capsule formulations of lisdexamfetamine?

Chewable tablets represent a smaller, more specialized market segment compared to oral capsules. Because there are fewer approved generic manufacturers for the chewable formulation, there is less competitive pressure, resulting in slower price erosion. Furthermore, chewable tablets require additional taste-masking excipients and specialized manufacturing processes, which increases the baseline cost. In contrast, oral capsules are produced in high volumes by a larger cohort of generic developers, driving rapid price erosion under surveyed retail acquisition cost models (NADAC).

Why do generic drug prices continue to fall during a supply shortage?

Generic drug pricing is decoupled from short-term supply dynamics due to PBM Maximum Allowable Cost (MAC) lists, long-term wholesaler prime vendor agreements, and Medicaid Best Price rules. Pharmacies cannot pass on higher acquisition costs to patients or insurers because PBM reimbursement rates are capped.

Additionally, generic manufacturers are bound by long-term supply contracts with major retail chains and wholesalers that lock in low pricing. Raising list prices during a shortage would trigger significant financial penalties, rebate liabilities, and long-term loss of market share once the shortage resolves.

How does the DEA allocate quotas to new generic manufacturers?

The DEA allocates Procurement Quotas to finished-dose generic manufacturers based on their historical sales volume, manufacturing capacity, and confirmed purchase orders. For new generic entrants who have recently received FDA approval (such as those approved in August 2023), the DEA estimates initial allocations based on projected market share.

However, because the total APQ is capped, the DEA must subtract quota from the branded manufacturer (Takeda) to allocate it to the new generic entrants. If the transfer of quota is slower than the shift in patient demand, it creates a temporary supply bottleneck where generic manufacturers have the capacity to make the drug but lack the legal quota to procure the API.

What is the clinical significance of lisdexamfetamine's pro-drug mechanism?

Lisdexamfetamine is a pro-drug of dextroamphetamine. It consists of the active molecule d-amphetamine covalently bonded to the amino acid l-lysine. The pro-drug is therapeutically inactive and must be converted to active d-amphetamine in the body:

• Conversion Site and Red Blood Cell Kinetics: The conversion does not occur in the digestive tract. Instead, after absorption, the amide bond is cleaved by hydrolytic enzymes located on the membrane of red blood cells. Clinical pharmacokinetic studies show that this enzymatic cleavage is highly consistent and saturable. The maximum rate of d-amphetamine generation is limited by the number of active red blood cell hydrolase sites, preventing the rapid release profile that occurs when abusing standard d-amphetamine.
• Controlled Substance Classification: This rate-limiting mechanism reduces the abuse liability of lisdexamfetamine compared to immediate-release amphetamines. However, because it still converts to d-amphetamine, the DEA maintains its Schedule II classification, subjecting the drug's entire supply chain to aggregate production quotas.

How do ADHD clinical endpoints shape prior authorization guidelines for stimulants?

Prior authorization (PA) guidelines for ADHD stimulants are heavily rooted in diagnostic criteria and clinical assessment scales:

• Diagnostic Criteria: Payers typically require documentation that the patient meets the DSM-5 criteria for ADHD, including symptoms persisting for at least 6 months and causing impairment in two or more settings (e.g., school/work and home).
• Clinical Rating Scales: Plans often require baseline and tracking scores from validated rating scales, such as the Vanderbilt ADHD Diagnostic Rating Scale for children or the Adult ADHD Self-Report Scale (ASRS) for adults. For prior authorization renewal, payers require documentation of a positive clinical response, defined as a significant reduction in symptom scores or improvement in academic/occupational functioning.

---

Sources

• Centers for Medicare & Medicaid Services (CMS): National Average Drug Acquisition Cost (NADAC) CSV extract, June 10, 2026. Medicaid.gov Prescribed Drugs
• U.S. Food and Drug Administration (FDA): Drug Shortages Database (openFDA /drug/shortages endpoint), June 10, 2026. FDA Drug Shortages
• Drug Enforcement Administration (DEA): "Established Aggregate Production Quotas for Schedule I and II Controlled Substances for 2026," 91 Fed. Reg. (January 5, 2026). Federal Register DEA Quotas
• U.S. Food and Drug Administration (FDA): "FDA Approves Multiple Generics of ADHD and BED Treatment (Vyvanse/lisdexamfetamine dimesylate)," August 28, 2023. FDA Press Release
• Currie J, Malinovskaya A.: "Manufacturing Supply Chains and Imports in the ADHD Drug Shortage," JAMA Health Forum, 2026;7(3):e260041. doi:10.1001/jamahealthforum.2026.0041. PMID: 41860539. PMCID: PMC13005163. PubMed